JDRF Canada salutes the recent discovery of Dr. Pere Santamaria and his team who have identified a novel approach to halt and possibly reverse the autoimmune attack that triggers type 1 diabetes (T1D), causing the destruction of insulin-producing pancreatic beta cells in T1D patients.
JDRF and Sanofi Announce Expansion of their Joint Research Collaboration to Include Development of Glucose Responsive Insulin Therapies for Treatment of Insulin-Dependent Diabetes
JDRF, the leading global organization funding and advocating for type 1 diabetes (T1D) research, and Sanofi US Services Inc., a subsidiary of Sanofi, one of the leading insulin manufacturers and a global pharmaceutical company, have entered into new agreements with four research organizations under ...
Researchers Show Novel Material Encapsulated Human Islet Cells Can Halt Type 1 Diabetes for Six Months
Researchers from the Massachusetts Institute of Technology (MIT), Boston Children’s Hospital, and several other institutions supported with JDRF funding have shown encapsulated human islet cells transplanted into mice can effectively halt type 1 diabetes (T1D) for up to six months without caus...
The University of Alberta is currently recruiting for its highly anticipated encapsulation trial located in Edmonton, Canada.
Lilly Canada and JDRF Canada have awarded an additional $120,000 in 2015 towards fellowship grants for promising investigators pursuing type 1 diabetes (T1D) research. Operating through the JDRF Canadian Clinical Trial Network (JDRF CCTN), this program is designed to provide the next generatio...
JDRF-funded research is making an impact on the lives of over 300,000 Canadians that are affected by T1D. World-renowned diabetes researcher, Dr. James Shapiro, shares his vision for a world without this disease.
Scientists have shown that disruption of the body’s internal clock system is involved in a range of diseases, from psychiatric to metabolic to cardiovascular.